EyePoint Pharmaceuticals (EYPT) Tops Q3 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts EYPT Hot Sheet
Join SI Premium – FREE
EyePoint Pharmaceuticals (NASDAQ: EYPT) reported Q3 EPS of ($0.54), $0.02 better than the analyst estimate of ($0.56). Revenue for the quarter came in at $10.5 million versus the consensus estimate of $10.06 million.
For earnings history and earnings-related data on EyePoint Pharmaceuticals (EYPT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Mizuho Downgrades EyePoint Inc. (EYPT) to Neutral 'on Negative P3 Data, Lack of Catalysts, Financing Overhang'
- Instacart (CART) Exploring Sale - The Information
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
